Overview:

The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein recognizes the host ACE2 receptor and is a major determinant of viral entry and neutralization (1). K417N mutation in the RBD region of spike protein has been identified in B.1.351 lineages. In addition to antigenic effect, K417N alters binding affinity to ACE-2 protein. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (2, 3).

Gene Aliases:

2019-nCoV RBD, SARS-CoV-2 spike RBD, novel coronavirus spike RBD, nCov spike RBD.

Genebank Number:

MN908947

Formulation:

Recombinant protein stored in 50mM sodium phosphate, pH 7.5, 300mM NaCl, 150mM imidazole.

References:

1. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235. 2. Harvey, WT, et al: SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021, 19:409–424. 3. Starr TN, et al: Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020, 182(5):1295-1310.